Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(10%)
Results Posted
50%(3 trials)

Phase Distribution

Ph not_applicable
1
10%
Ph phase_2
6
60%
Ph phase_1
1
10%
Ph phase_3
2
20%

Phase Distribution

1

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
2(20.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Withdrawn2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 26 (60.0%)
Phase 32 (20.0%)
N/A1 (10.0%)

Trials by Status

not_yet_recruiting110%
completed660%
recruiting110%
withdrawn220%

Recent Activity

1 active trials
Showing 5 of 10
not_yet_recruitingphase_2

SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

NCT07700667
completedphase_1

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT05546853
recruitingphase_2

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

NCT05472259
completedphase_2

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.

NCT01858649
completedphase_3

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

NCT01926236
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07700667Phase 2

SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

Not Yet Recruiting
NCT05546853Phase 1

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Completed
NCT05472259Phase 2

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

Recruiting
NCT01858649Phase 2

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.

Completed
NCT01926236Phase 3

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

Completed
NCT01063075Phase 2

A Study in Advanced Solid Tumors

Completed
NCT00577109Phase 2

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Withdrawn
NCT00069108Phase 3

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

Completed
NCT00448136Phase 2

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Completed
NCT01631539Not Applicable

Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10